Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch + Lomb Corporation (BLCO) filed a Form 4 showing EVP & CFO Sam Eldessouky completed an administrative equity transaction on 25-Jul-2025. Exactly 3,996 common shares were withheld by the company (transaction code “F”) at an indicated price of $14.32 to cover tax obligations triggered by the vesting of restricted share units. No open-market buying or selling occurred.
After the tax-settlement, Eldessouky’s direct beneficial ownership stands at 278,299 BLCO shares. The filing lists no derivative security activity and leaves his overall stake largely unchanged. Because the shares were surrendered to the issuer rather than sold to investors, the event is considered routine and is unlikely to influence the stock’s supply-demand dynamics or signal a change in the executive’s outlook.
Bausch + Lomb (NYSE:BLCO) filed an 8-K detailing completion of a €675 million senior secured floating-rate note offering due 2031 and a comprehensive debt refinancing.
The company also executed a Third Amendment to its credit agreement, adding $2.325 billion of term loans maturing 2031 and replacing its $500 million revolver with a new $800 million facility maturing 2030.
Proceeds were used to fully repay the outstanding revolver and refinance all term A and B loans due 2027, effectively pushing major maturities out by four years and increasing available liquidity by $300 million.
The notes bear 3-month EURIBOR + 3.875%; term loans carry SOFR + 4.25% (base-rate +3.25%). The amendment raises the maximum first-lien net leverage covenant to 5.75×, stepping down over time, and retains customary covenants and events of default.
Bausch + Lomb announced significant debt refinancing activities on June 18, 2025. The company has priced an offering of €675 million senior secured floating rate notes due 2031, increased from the initially announced €600 million. The notes will be sold at 99.500% of principal value.
The company is also pursuing a refinancing package including a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and a $800 million new revolving credit facility. These proceeds will be used to:
- Repay outstanding borrowings under existing revolving credit facility
- Refinance term A loans due 2027
- Refinance term B loans due 2027
- Pay related fees and expenses
The notes offering is expected to close on June 26, 2025, subject to customary conditions. The notes will be offered to qualified institutional buyers in the US under Rule 144A and internationally under Regulation S, with first-priority liens on assets securing the company's credit agreement.